Traws Pharma deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA, citing mutagenic concerns. The company is advancing backup antiviral candidates with similar pharmacokinetic profiles while maintaining cash runway through Q1 2027.